Strasbourg

• Antiplatelet therapy after successful percutaneous coronary intervention for chronically occluded coronary artery: A prospective, multicentr … Recruiting
  2023-508148-23-01 5 2024-12-02 chronically occluded coronary artery
• Evaluation of the addition of Everolimus to 177Lu-DOTATATE in the treatment of grades 2 and 3 refractory meningioma: a phase IIb clinical tr … Recruiting
  2023-508400-38-00 4 2024-11-29 meningioma
• Double-blind Placebo-Controlled Randomized Clinical Trial of Mineralocorticoid Receptor Blockade With Eplerenone After Renal Transplantation … Recruiting
  2024-517408-12-00 5 2024-11-28 Patient in end-stage renal disease candidate for a kidney transplant
• Carboplatin + Paclitaxel + Cetuximab (PCC) after failure of first line Immune checkpoint inhibitor with or without chemotherapy in recurrent … Recruiting
  2024-512297-96-01 4 2024-11-26 Head and neck squamous cell carcinoma
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• Randomized Phase II, 2-arm Study of Immunomodulation with Atezolizumab concomitant with High Dose Radiation (SBRT) Versus SBRT Alone in Pati … Recruiting
  2024-511313-38-00 4 2024-11-17 Soft Tissue Sarcoma
• Induction therapy for lupus nephritis with no added oral corticosteroids : An open label randomised multicentre controlled trial comparing … Recruiting
  2024-516242-19-00 5 2024-11-05 lupus nephritis
• A prospective, multicentre, open-label, randomized, Phase II study of Pembrolizumab in combination with neo-adjuvant EC-Paclitaxel regimen i … Recruiting
  2024-514899-41-00 4 2024-10-31 Breast cancer
• LENVABLA Lenvatinib in neo-adjuvant and adjuvant therapy for poor-prognosis BCLC A HepatoCellular Carcinoma treated by percutaneous ablatio … Recruiting
  2024-514606-31-00 4 2024-10-29 Patients with Biopsy-proven or radiologically-suggested BCLC A HCC eli
• FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting
  2024-515300-39-00 4 2024-10-18 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF G
• A multi-center randomized phase II study comparing corticosteroids alone versus corticosteroids and extracorporeal photopheresis as first-li … Recruiting
  2023-508614-41-00 4 2024-10-15 The study will be proposed to all adult patients receiving an allogene
• An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to ch … Recruiting
  2024-516782-36-00 4 2024-10-15 metastatic or recurrent endometrial or ovarian carcinosarcoma
• Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag … Recruiting
  2023-507482-26-00 5 2024-10-04 Castrate-resistant prostate cancer with oligometastases on functional
• PRODIGE 98- AMPIRINOX : Randomized, multicenter, Phase III trial of adjuvant chemotherapy with modified FOLFIRINOX versus capecitabine or ge … Recruiting
  2024-511070-68-01 5 2024-09-24 Ampullary adenocarcinoma
• Study evaluating whether giving 177Lu-PSMA-617 to men having a spreading prostate cancer which does not respond well to the current standard … Recruiting
  2022-502408-57-00 5 2024-09-04 Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients hav
• PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting
  2024-515297-27-00 5 2024-08-14 colon carcinoma
• A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro … Recruiting
  2023-508005-24-00 5 2024-08-01 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa … Recruiting
  2023-508260-30-01 5 2024-07-30 Patients with poor prognostic OVARian cancers based on the tumor prima
• Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizu … Recruiting
  2024-515788-73-00 4 2024-07-30 MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IM
• Immunotherapy with dostarlimab for locally advanced or metastatic cancer (non-colorectal/non-endometrial) with tumor dMMR/MSI Recruiting
  2023-505298-34-00 4 2024-07-18 Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanc
• Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients with Advanced … Recruiting
  2023-508178-27-00 9 2024-07-10 Participants with Advanced KRASG12C-Mutated Solid Tumors
• CARE : Impact of Regorafenib in combination with multimodal metronomic chemotherapy (cyclophosphamide, capecitabine, and low-dose aspirin) o … Recruiting
  2023-509761-21-00 5 2024-07-08 Metastatic colorectal cancer
• Adjuvant therapy in high risk adrenocortical carcinoma (ADIUVO-2) Recruiting
  2022-500013-32-01 5 2024-07-05 Adrenocortical carcinoma

Showing 121–144 of 377 trials